Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7493476 | 0.98 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4PNMTKEAP1 | |
| Hydrochloric Acid SCHEMBL7489463 | 0.98 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4PNMTKEAP1 | |
| SCHEMBL5711609 | 0.81 | SLC6A3 (0.37) | SLC6A3SLC6A2SLC6A4ALOX5 | |
| SCHEMBL6640956 | 0.81 | PNMT (0.44) | SLC6A3SLC6A2SLC6A4PNMT | |
| SCHEMBL13692462 | 0.81 | PNMT (0.44) | SLC6A3SLC6A2SLC6A4PNMT | |
| SCHEMBL3060436 | 0.81 | PNMT (0.44) | SLC6A3SLC6A2SLC6A4PNMT | |
| SCHEMBL27572442 | 0.74 | — | — | |
| SCHEMBL25547088 | 0.74 | — | — | |
| SCHEMBL7676109 | 0.74 | HTR2A (0.36) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL22863972 | 0.72 | SLC6A3 (0.41) | SLC6A3PNMTKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175420-A2 | PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2000037469-A2 | PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-29 | — | — | WO | claimed |
| CN-101827847-A | Purine derivatives as adenosine al receptor ligands | NOVARTIS AG | 2010-09-08 | — | — | CN | disclosed |
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2205601-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050199-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| EP-0942900-A4 | STEREOSPECIFIC PREPARATION OF CHIRAL 1-ARYL- AND 1-HETEROARYL-2-SUBSTITUTED ETHYL-2-AMINES | AVENTIS PHARM PROD INC (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1175420-A2 | PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000037469-A2 | PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-29 | — | — | WO | disclosed |
| EP-0942900-A1 | STEREOSPECIFIC PREPARATION OF CHIRAL 1-ARYL- AND 1-HETEROARYL-2-SUBSTITUTED ETHYL-2-AMINES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998011064-A1 | STEREOSPECIFIC PREPARATION OF CHIRAL 1-ARYL- AND 1-HETEROARYL-2-SUBSTITUTED ETHYL-2-AMINES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | ADORA2A, ADORA1, ADORA3 | SLC6A3 1246/4885SLC6A2 879/4885SLC6A4 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.